Paper Details

  1. Home
  2. Paper Details

Case report: Efficacy and safety of regorafenib plus fluorouracil combination therapy in the treatment of refractory metastatic colorectal cancer.

Author: AbdelrahimMaen, AjewoleVeronica B, EsmailAbdullah, HaqueEmaan, MuhsenIbrahim N, MylavarapuCharisma, UmoruGodsfavour

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.

Overview

This retrospective review examined the use of regorafenib + 5FU combination therapy for metastatic colorectal cancer (mCRC) in patients who had received at least two other lines of therapy. The combination was found to be effective in achieving disease control in a small sample of patients. Further studies are needed to confirm these findings and to compare the efficacy and safety of this combination with other therapies.
Paper Details　
Original Abstract of the Article :
BACKGROUND: More than half of patients with colorectal cancer (CRC) present with metastatic disease or develop recurrent disease on first-line and second-line options. Treatment beyond the second line remains an area of unmet need for patients with progressive or recurrent disease. METHODS: We retr...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9822717/

データ提供：米国国立医学図書館（NLM）

A New Hope for Refractory Metastatic Colorectal Cancer: Exploring Regorafenib + 5FU Combination Therapy

Metastatic colorectal cancer (mCRC), a challenging condition that spreads beyond the original tumor site, can be as relentless as a desert sandstorm. This research explores a new combination therapy, regorafenib plus fluorouracil (5FU), for the treatment of refractory mCRC. The study investigates the efficacy and safety of this combination, seeking to find a new weapon in the fight against this aggressive cancer.

Regorafenib + 5FU: A Potential Oasis in the Desert of mCRC

The research suggests that regorafenib + 5FU combination therapy might be a promising treatment option for refractory mCRC. This finding offers hope for patients with limited treatment options, much like finding a hidden spring in a parched desert. The study highlights the need for further research to confirm the efficacy and safety of this combination therapy.

Navigating Refractory mCRC: Finding a Path to Hope

This research underscores the importance of exploring new treatment options for refractory mCRC. It's a journey of discovery, much like a desert explorer venturing into uncharted territory. The study provides valuable insights into the potential of new combination therapies, offering hope for a brighter future for patients facing this challenging condition.

Dr.Camel's Conclusion

This research represents a glimmer of hope for patients with refractory mCRC. It's a journey of resilience, much like a desert traveler facing a harsh and unforgiving environment. I, Dr. Camel, believe that this study will inspire continued research and development of new treatment strategies, offering a potential oasis in the desert of mCRC.
Date :
  1. Date Completed n.d.
  2. Date Revised 2023-01-11
Further Info :

Pubmed ID

36620581

DOI: Digital Object Identifier

PMC9822717

Related Literature

Article Analysis
・Side Effects of regorafenib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.